Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy

By sjmartinez • July 11, 2022

Lechner MG, Cheng MI, Patel AY, Hoang AT, Yakobian N, Astourian M, Pioso MS, Rodriguez ED, McCarthy EC, Hugo W, Angell TE, Drakaki A, Ribas A, Su MA. Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. J Immunol. 2022 Jul 11:ji2200244. doi: 10.4049/jimmunol.2200244. Epub ahead of print. PMID: 35817515.

Tags: Endocrinology, Hematology/Oncology, Publications

Closing the Distance: A Qualitative Study to Identify Equitable Innovations for Rural Thyroid Cancer Treatment

Huston-Paterson HH, Mao YV, Hughes EG, Bobanga I, Wu JX, Yeh MW. Closing the Distance: A Qualitative Study to Identify Equitable Innovations for Rural Thyroid[...]

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

Perry AS, Hadad N, Chatterjee E, Jimenez-Ramos M, Farber-Eger E, Roshani R, Stolze LK, Betti MJ, Zhao S, Huang S, Martens L, Kendall TJ, Thone[...]

Evaluation of dimethandrolone undecanoate in non-human primates as a candidate for long-acting injectable male contraceptive

Bunin DI, Kim K, Parman T, Gahagen J, Zelinski MB, Adevai T, Wang C, Tang L, Iyer L, Endsley A, Blithe DL, Lee MS. Evaluation[...]